TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03701230

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: low temperature rota-flush solution
Description: Patients with severe calcified lesions undergoing RA were performed with low temperature rota-flush solution. The investigators used thermal insulation equipment to keep rota-flush solution at 0～5℃. The EKG and blood pressure were monitored during the RA procedure. After RA, the investigators monitored levels of myocardial injury biomarkers for 3 days every 8 hours.
Study: NCT01424579

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Actual Diacutaneous Fibrolysis
Description: Diacutaneous Fibrolysis is a non-invasive physiotherapeutic technique applied by means of a set of metallic hooks ending in a spatula with bevelled edges that allow a deeper and more precise application, which could not be achieved manually. Appropriate hook is applied following the intermuscular septum between the muscles with an anatomical or functional relationship with the painful structure, in a centripetal direction towards the pain location, in order to release adherences between musculoskeletal structures.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Diactuaneous Fibrolysis
Description: Placebo Diacutaneous Fibrolysis was applied at a superficial level and, instead of fibrolysis, a pinch of skin was held with the thumb of the palpatory hand and the tip of the spatula, without any action taking place on the deep tissular levels.
Study: NCT01048853

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lymph Node Mapping
Description: Undergo lymphatic mapping with sentinel lymph node biopsy
Study: NCT01424579

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Protocolized physiotherapeutic Treatment
Description: Tree weeks of daily therapeutic exercises, analgesic electrotherapy and cryotherapy.

Intervention type: OTHER
Group type: OTHER
Intervention: Protocolized physiotherapeutic Treatment
Description: Tree weeks of daily therapeutic exercises, analgesic electrotherapy and cryotherapy.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Protocolized physiotherapeutic Treatment
Description: Tree weeks of daily therapeutic exercises, analgesic electrotherapy and cryotherapy.
Study: NCT01971892

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non Invasive ventilation (facial mask and NIV ventilator)
Description: Non invasive ventilation (NIV) which associated pressure support ventilation (PSV: 5 to 15 cmH2O) and positive end expiratory pressure (PEEP: 5 to 10 cmH2O). NIW will be delivered through a facial mask with either NIV ventilator or ICU ventilator with NIV option

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard oxygen therapy with facial mask
Description: facial Venturi mask
Study: NCT00401154

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stationary Cycling
Description: Use of a stationary bicycle for exercise
Study: NCT02856087

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: High dose Remifentanil
Description: remifentanil infusion at 4ng/ml of Ce

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High dose Remifentanil
Description: remifentanil infusion at 4ng/ml of Ce

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naloxone
Description: naloxone infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Low dose remifentanil
Description: remifentanil infusion at 1ng/ml of Ce

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal Saline
Description: normal saline infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: normal saline infusion
Study: NCT01048853

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Salpingo-Oophorectomy
Description: Undergo hysterectomy with or without salpingo-oophorectomy
Study: NCT02023008

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: yoga therapy
Description: Undergo integral yoga intervention with videoconferencing

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: internet-based intervention
Description: Undergo integral yoga intervention with videoconferencing

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies
Study: NCT01048853

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sentinel Lymph Node Biopsy
Description: Undergo lymphatic mapping with sentinel lymph node biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo hysterectomy with or without salpingo-oophorectomy
Study: NCT04500171

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CDC Colorectal cancer screening for life brochure: SAM + CAM SMOG
Description: Suitability and Comprehensibility Assessment of Materials (SAM + CAM). The SAM + CAM is comprised of 22 evaluation items within the 6 original categories. The SMOG is a readability assessment tool that uses a formula to calculate grade levels by the number of sentences, total number of words in the sentences, and the number of polysyllabic words

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Colocare Instruction Sheet: SAM + CAM - Superior rating SMOG - 5th Grade Level
Description: Suitability and Comprehensibility Assessment of Materials (SAM + CAM). The SAM + CAM is comprised of 22 evaluation items within the 6 original categories. The SMOG is a readability assessment tool that uses a formula to calculate grade levels by the number of sentences, total number of words in the sentences, and the number of polysyllabic words
Study: NCT00628940

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: PET images with 18F-fluoromethylcholine
Description: sequential PET images with 18F-fluoromethylcholine
Study: NCT02735486

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ginger drink
Description: 300 ml ginger drink

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo: Super pure water
Description: Placebo: Super pure water
Study: NCT02117401

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mivacurium chloride
Description: intravenously injected during induction with the dose according to allocated group, and intravenously injected with the dose of 0.1 mg/kg when T1 recovers to 25% during period of maintenance.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mivacurium chloride
Description: intravenously injected during induction with the dose according to allocated group, and intravenously injected with the dose of 0.1 mg/kg when T1 recovers to 25% during period of maintenance.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mivacurium chloride
Description: intravenously injected during induction with the dose according to allocated group, and intravenously injected with the dose of 0.1 mg/kg when T1 recovers to 25% during period of maintenance.
Study: NCT02233114

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yogic exercises
Description: Yogic exercises (YE) - 2 hours per week, 1h in each session

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physiotherapy
Description: Physiotherapy (low intensity cardiovascular training and strength training) - 2 hours per week, 1 h in each session
Study: NCT01952197

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Passive Leg Raise
Description: The intervention is made on all adult patients receiving CPR by the ambulance crew. The leg raise is performed during the first minutes of CPR (limit 5 min) and will continue as long as the patients receive chest compression. In Spain the patient is immediate randomized by envelope. If the patient is randomized to PLR, the ambulance crews use a special folding stool that allows the legs to be raised about 20 degrees.
Study: NCT04160468

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exebacase
Description: Participants will receive a single IV infusion of exebacase in addition to SoCA selected by the investigator. Participants with normal renal function or mild renal impairment will be administered a dose of 18 mg; participants with moderate or severe renal impairment will be administered a dose of 12 mg of exebacase; participants with end-stage renal disease, including those on hemodialysis, will be administered a dose of 8 mg of exebacase.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive a single IV infusion of placebo in addition to SoCA selected by the investigator.
Study: NCT04167735

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hearing Aid without Reverberation Canceller (RevC).
Description: Each participant will be fitted with the 2 different Sound Changing principles on the same hearing aid, saved to 2 manual programs (ensures exact same hearing loss compensation for each intervention). Reverberation Canceller principle is a sound processing algorithm to remove reverberation from a speech signal to improve the speech intelligibility and comfort. The active comparator condition is without Reverberation Canceller principle enabled.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hearing Aid Reverberation Canceller enabled (RevC_1)
Description: Each participant will be fitted with the 2 different Sound Changing principles on the same hearing aid, saved to 2 manual programs (ensures exact same hearing loss compensation for each intervention). Reverberation Canceller principle is a sound processing algorithm to remove reverberation from a speech signal to improve the speech intelligibility and comfort. The experimental condition applies the Reverberation Canceller and is predicted to provide a benefit in reverberant room simulations.
Study: NCT02142192

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: natalizumab
Description: Administered as specified in the treatment arm
Study: NCT03255291

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Risk Assessment App
Description: The App provides participants with personalized risk results for colon cancer, breast cancer (women), heart disease, diabetes, and stroke.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Risk Assessment App
Description: The App provides participants with personalized risk results for colon cancer, breast cancer (women), heart disease, diabetes, and stroke.
Study: NCT02117401

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mivacurium chloride
Description: intravenously injected during induction with the dose according to allocated group, and intravenously injected with the dose of 0.1 mg/kg when T1 recovers to 25% during period of maintenance.
Study: NCT04313426

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Integrative Yoga Therapy
Description: Integrative Yoga Therapy included personalised yoga therapy sessions including their standard care, yoga movements, relaxation, meditation, breathing practices and yoga counselling sessions.
Study: NCT02913820

Intervention type: OTHER
Intervention: snowfall > 5cm/day
Description: the number of myocardial infarctions of every day analysed in this study will be correlated with the respective values of snowfall
Study: NCT02117401

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: midazolam
Description: Before induction: after moving into operating room, oral administration with dose of 0.5 mg/kg or mixed with ketamine (midazolam 10 mg+ ketamine 100 mg) with dose of 0.1 ml/kg by intramuscular route for uncooperative children~Induction: for children who didn't receive mixture of midazolam and ketamine before induction, it will be given with the dose of 0.05 ml/kg
Study: NCT03762837

Intervention type: OTHER
Intervention: Benigh gallbladder diseases
Description: We aim to observe the relationship between the benigh gallbladder diseases and gallbladder cancer, and we will not take any actions to interrupt.
Study: NCT00735930

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alvocidib Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT04529876

Intervention type: DRUG
Intervention: Tofacitinib
Description: Tofacitinib claim is used as the reference group.

Intervention type: DRUG
Intervention: Abatacept
Description: Abatacept claim is used as the exposure group.
Study: NCT04674982

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: a vibrating device
Description: vibrating device (Mini vibrator, 8.5 cm, 92-100 Hz)
Study: NCT03002792

Intervention type: PROCEDURE
Intervention: general anesthesia
Description: nitrous oxide, sevoflurane, propofol, cisatracurium, fentanyl for induction and maintenance with sevoflurane
Study: NCT02537509

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of cholecalciferol
Study: NCT01040793

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olodaterol (BI 1744)
Description: Comparison of low and high dose on exercise endurance time in COPD patients
Study: NCT02117401

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: midazolam
Description: Before induction: after moving into operating room, oral administration with dose of 0.5 mg/kg or mixed with ketamine (midazolam 10 mg+ ketamine 100 mg) with dose of 0.1 ml/kg by intramuscular route for uncooperative children~Induction: for children who didn't receive mixture of midazolam and ketamine before induction, it will be given with the dose of 0.05 ml/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: midazolam
Description: Before induction: after moving into operating room, oral administration with dose of 0.5 mg/kg or mixed with ketamine (midazolam 10 mg+ ketamine 100 mg) with dose of 0.1 ml/kg by intramuscular route for uncooperative children~Induction: for children who didn't receive mixture of midazolam and ketamine before induction, it will be given with the dose of 0.05 ml/kg
Study: NCT02287779

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHP626

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01836757

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MethylSulfonylMethane (MSM)
Description: Intervention is MSM 3 gr twice a day for 26 weeks (6 gr/day total)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02117401

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ketamine
Description: mixed with ketamine (midazolam 10 mg+ ketamine 100 mg) with dose of 0.1 ml/kg by intramuscular route for uncooperative children~Induction: for children who didn't receive mixture of midazolam and ketamine before induction, it will be given with the dose of 0.05 ml/kg
Study: NCT02577809

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine100
Description: 100mcg added to the spinal anaesthetic

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine50
Description: 50mcg added to the spinal anaesthetic

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: 25mcg Fentanyl added to the spinal anaesthetic
Study: NCT01040793

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Comparison of low and high dose and placebo on exercise endurance time in COPD patients

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olodaterol (BI1744)
Description: Comparison of low and high dose on exercise endurance time in COPD patients

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olodaterol (BI 1744) placebo
Description: Placebo that represents olodaterol
Study: NCT02166853

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sevoflurane
Description: Sedation with inhaled sevoflurane

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: midazolam
Description: Sedation with intravenous midazolam
Study: NCT05141630

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: sentinel lymph node biopsy or targeted axillary dissection alone
Description: sentinel lymph node biopsy or targeted axillary dissection alone
Study: NCT01560819

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gut Microbial Transplantation
Description: Each participant received Gut Microbial Transplantation (GMT) as retention enema over a period of 1 hour (60mL enema every 15 minutes) daily for 5 days. Although 240mL of GMT solution was prepared for each participant, the final administered dose was dependent on the subject's comfort and willingness to proceed with the next enema, which was assessed after each enema infusion. Subjects were monitored for 30 minutes after GMT for any immediate adverse events and discharged.
Study: NCT04096339

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Colonoscopy followed by EGD
Description: Colonoscopy is done first followed by EGD

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: EGD followed by Colonoscopy
Description: Esophagoduodenoscopy (EGD) is done first followed by Colonoscopy
Study: NCT02851719

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PFMT with biofeedback + Home PFMT
Description: 24 outpatient sessions PFMT with biofeedback (twice a week). Simultaneously, it was prescribed a home exercise daily program during three months (supervised treatment).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PFMT without biofeedback + Home PFMT
Description: 24 outpatient sessions PFMT without biofeedback (twice a week). Simultaneously, it was prescribed a home exercise daily program during three months (supervised treatment).
Study: NCT02968719

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Donepezil TDS Version A
Description: Donepezil Hydrochloride Transdermal Delivery System (5mg and 10 mg Version B)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil TDS Version A
Description: Donepezil Hydrochloride Transdermal Delivery System (5mg and 10 mg Version B)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Donepezil TDS Version B
Description: Donepezil Hydrochloride Transdermal Delivery System (5 mg and 10 mg Version B)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil TDS Version B
Description: Donepezil Hydrochloride Transdermal Delivery System (5 mg and 10 mg Version B)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aricept
Description: Aricept (5 mg and 10 mg) Donepezil Hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aricept
Description: Aricept (5 mg and 10 mg) Donepezil Hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil TDS Version D
Description: Donepezil Hydrochloride Transdermal Delivery System (5 mg Version D)
Study: NCT02577809

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyperbaric Bupivicaine
Description: 1.8ml 0.5% spinal bupivicaine with dextrose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyperbaric Bupivicaine
Description: 1.8ml 0.5% spinal bupivicaine with dextrose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyperbaric Bupivicaine
Description: 1.8ml 0.5% spinal bupivicaine with dextrose
Study: NCT02968719

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil TDS Version D
Description: Donepezil Hydrochloride Transdermal Delivery System (5 mg Version D)
Study: NCT03255291

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Risk Assessment App
Description: The App provides participants with personalized risk results for colon cancer, breast cancer (women), heart disease, diabetes, and stroke.
Study: NCT02106975

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ascorbic Acid
Description: Intervention
Study: NCT03255291

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Risk Assessment App
Description: The App provides participants with personalized risk results for colon cancer, breast cancer (women), heart disease, diabetes, and stroke.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Risk Assessment App
Description: The App provides participants with personalized risk results for colon cancer, breast cancer (women), heart disease, diabetes, and stroke.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Risk Assessment App
Description: The App provides participants with personalized risk results for colon cancer, breast cancer (women), heart disease, diabetes, and stroke.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Audio Recording - Sleep
Description: -Participants imagine themselves improving sleep hygiene

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Audio Recording - Sleep
Description: -Participants imagine themselves improving sleep hygiene

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Audio Recording - Sleep
Description: -Participants imagine themselves improving sleep hygiene

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Surveys
Description: Assesses information comprehension, intentions, perceived risk and severity worry, self- efficacy, response efficacy, affect, race, education, age, numeracy, graph literacy, and exercise and sleep behaviors.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Surveys
Description: Assesses information comprehension, intentions, perceived risk and severity worry, self- efficacy, response efficacy, affect, race, education, age, numeracy, graph literacy, and exercise and sleep behaviors.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Surveys
Description: Assesses information comprehension, intentions, perceived risk and severity worry, self- efficacy, response efficacy, affect, race, education, age, numeracy, graph literacy, and exercise and sleep behaviors.
Study: NCT02968719

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil TDS Version E
Description: Donepezil Hydrochloride Transdermal Delivery System (5 mg Version E)
Study: NCT02577809

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Indomethacin
Description: 100mg Indomethacin suppository
Study: NCT02106975

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo: 5% Dextrose in water
Description: Placebo
Study: NCT01132365

Intervention type: DEVICE
Intervention: any knee joint arthroplasty device
Description: Cohort consist of all consented patients receiving knee arthroplasty
Study: NCT01307982

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fundoplication
Description: During fundoplication surgery, the upper curve of the stomach (the fundus) is wrapped around the esophagus and sewn into place so that the lower portion of the esophagus passes through a small tunnel of stomach muscle. This surgery strengthens the valve between the esophagus and stomach (lower esophageal sphincter), which stops acid from backing up into the esophagus as easily.